Get in touch
Our Client Services team is on hand to help. Please call us at 866.776.5907, Option 3.
EGFR
- Immunohistochemistry (IHC)
Epidermal Growth Factor Receptor (EGFR) overexpression can occur in a variety of tumor types, including breast, prostate, ovarian, brain, lung and predominantly squamous cell carcinomas. Tumors that express EGFR are associated with a poor prognosis and a shorter disease-free survival. Most colon carcinomas will show expression of EGFR in more than 1% of the invasive tumor cells. Patients whose tumor expresses EGFR and are wild-type for KRAS mutation are eligible for cetuximab therapy based on the status of RAS mutation.
EGFR immunohistochemistry (clone D38B1; non-mutation specific) has no relationship to determining clinical response to EGFR–tyrosine kinase inhibitors in lung adenocarcinoma. The appropriate study to evaluate somatic mutations in the tyrosine kinase domain of EGFR gene in lung adenocarcinomas is EGFR Mutation Analysis by either PCR or NGS methods.
Turnaround time
Global: 2 Day, Tech-Only (stain only): 1 Day
Level of Service
- Global
- Technical Only
New York Approved: Yes
Specimen Requirements
A formalin-fixed, paraffin-embedded (FFPE) tissue block is preferred specimen type or one (1) unbaked, unstained slide for H&E staining (required) and two to three (2-3) positively charged unstained slides (all cut at 4-5 microns) for each test/antibody ordered. Block and slide identifiers should be clearly written and match exactly with the specimen ID and specimen labeling as noted on the requisition.
Storage and Transportation
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. NYS clients please provide date and time of Collection.
CPT Code(s)*
88342 x 1 or 88341 x 1
*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.
Last Updated: February 12, 2025